Patients demographic, cumulative clinical data and autoantibodies profile by complement group
| Normal complement (n=116) | Persistent low complement (n=79) | Fluctuant complement (n=75) | p Value | |
| Females, n (%) | 107 (92.2) | 70 (88.6) | 65 (86.7) | 0.439 |
| Age at diagnosis, mean, years (SD) | 36.4 (16.5) | 32.4 (14.7) | 32.7 (15.8) | 0.1397 |
| Follow-up, median, years (IQR) | 6.4 (8.2) | 6.1 (7.6) | 9.2 (5.6) | 0.345 |
| Mean age at end follow-up (SD) | 43.5 (17.3) | 38.5 (15.3) | 41.9 (15.4) | 0.394 |
| Cutaneous lupus, n (%) | 76 (65.5) | 50 (63.3) | 44 (58.7) | 0.773 |
| Oral ulcers, n (%) | 24 (20.7) | 19 (24.1) | 20 (26.7) | 0.624 |
| Serositis, n (%) | 37 (31.9) | 15 (18.9) | 17 (22.7) | 0.102 |
| Arthritis, n (%) | 59 (50.9) | 47 (59.5) | 35 (46.7) | 0.261 |
| Neurological involvement, n (%) | 15 (12.9) | 7 (8.9) | 7 (9.3) | 0.598 |
| Renal involvement, n (%) | 57 (49) | 44 (56) | 56 (75) | 0.002 |
| Leucopaenia and/or lymphopaenia, n (%) | 35 (30.2) | 39 (49.4) | 34 (45.3) | 0.007 |
| Thrombocytopaenia n (%) | 20 (17.2) | 28 (35.4) | 25 (33.3) | 0.026 |
| Haemolytic anaemia n (%) | 2 (1.7) | 7 (8.9) | 6 (8) | 0.057 |
| ANA positive, n (%) | 109 (94) | 77 (97.5) | 68 (90.7) | 0.202 |
| Anti-dsDNA positive, n (%) | 52 (44.8) | 54 (68.3) | 57 (76) | <0.001 |
| Anti-Sm positive, n (%) | 12 (10.3) | 10 (12.7) | 8 (10.7) | 0.882 |
| Lupus anticoagulant positive, n (%) | 14 (12.1) | 16 (20.2) | 11 (14.7) | 0.254 |
| Anticardiolipins positive, n (%) | 17 (14.7) | 20 (25.3) | 13 (17.3) | 0.405 |